PubRank

Naoya Ikeda

Author PubWeight™ 26.30‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 2005 4.42
2 Prognostic significance of HIF-1 alpha overexpression in human pancreatic cancer. Anticancer Res 2004 1.42
3 The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with MMP-9 serves as an informative prognostic indicator for colorectal cancer. Clin Cancer Res 2004 1.34
4 Prognostic significance of localized p27Kip1 and potential role of Jab1/CSN5 in pancreatic cancer. Oncol Rep 2004 1.07
5 A novel small-molecule compound targeting CCR5 and CXCR3 prevents acute and chronic allograft rejection. Transplantation 2005 1.03
6 RNA-induced silencing complex (RISC) Proteins PACT, TRBP, and Dicer are SRA binding nuclear receptor coregulators. Proc Natl Acad Sci U S A 2013 0.98
7 Genistein induces cell growth inhibition in prostate cancer through the suppression of telomerase activity. Int J Urol 2005 0.96
8 Primary leiomyoma of the liver: report of a case. Surg Today 2006 0.93
9 Activation of human liver sinusoidal endothelial cell by human platelets induces hepatocyte proliferation. J Hepatol 2010 0.90
10 Dual role of vascular endothelial growth factor in hepatic ischemia-reperfusion injury. Transplantation 2005 0.86
11 Platelets prevent acute liver damage after extended hepatectomy in pigs. J Hepatobiliary Pancreat Sci 2010 0.86
12 Function of the vascular endothelial growth factor receptors Flt-1 and Flk-1/KDR in the alloimmune response in vivo. Transplantation 2005 0.84
13 Effects of thrombopoietin on growth of hepatocellular carcinoma: Is thrombopoietin therapy for liver disease safe or not? Hepatol Res 2012 0.84
14 Effects of pancrelipase on nonalcoholic fatty liver disease after pancreaticoduodenectomy. J Hepatobiliary Pancreat Sci 2013 0.84
15 55 kDa nuclear matrix protein (nmt55) mRNA is expressed in human prostate cancer tissue and is associated with the androgen receptor. Int J Cancer 2003 0.82
16 A potent antiangiogenic factor, endostatin prevents the development of asthma in a murine model. J Allergy Clin Immunol 2005 0.82
17 Epidermal growth factor receptor mutations in malignant pleural and peritoneal mesothelioma. J Clin Pathol 2012 0.81
18 A comparison of epidermal growth factor receptor expression in malignant peritoneal and pleural mesothelioma. Pathol Int 2012 0.81
19 Role of the ICOS-B7h costimulatory pathway in the pathophysiology of chronic allograft rejection. Transplantation 2005 0.81
20 Bone marrow chimerism and tolerance induced by single-dose cyclophosphamide. J Surg Res 2004 0.79
21 Significance and therapeutic potential of prostaglandin E2 receptor in hepatic ischemia/reperfusion injury in mice. Hepatology 2005 0.79
22 Prognostic significance of death-associated protein-kinase expression in hepatocellular carcinomas. Anticancer Res 2003 0.79
23 Platelets prevent acute hepatitis induced by anti-fas antibody. J Gastroenterol Hepatol 2011 0.79
24 Platelet transfusion improves liver function in patients with chronic liver disease and cirrhosis. Tohoku J Exp Med 2013 0.78
25 Pd(2+)-incorporated perovskite CaPd3B4O12 (B = Ti, V). Inorg Chem 2013 0.77
26 Relationship between sensitivity to dyspnea and fluctuating peak expiratory flow rate in the absence of asthma symptoms. Asia Pac Allergy 2012 0.75
27 The breakdown of apoptotic mechanism in the development and progression of colorectal carcinoma. Anticancer Res 2004 0.75
28 [A case of local relapsed rectal cancer responding to low-dose S-1]. Gan To Kagaku Ryoho 2010 0.75
29 [A case of drug-induced hypersensitivity syndrome caused by levofloxacin used for treating pulmonary tuberculosis]. Kekkaku 2014 0.75
30 [Laparoscopic Gastrectomy for Gastric Adenocarcinoma of the Fundic Gland Type - Report of a Case]. Gan To Kagaku Ryoho 2016 0.75
31 Determination of optimum process parameters for peroxidase-catalysed treatment of bisphenol A and application to the removal of bisphenol derivatives. Environ Technol 2010 0.75
32 [A novel molecular target therapeutics for refractory prostate cancer]. Nihon Rinsho 2002 0.75